Recent Press Releases

Scientists take a step closer to developing vaccine against C. difficile

Scientists take a step closer to developing vaccine against C. difficile Posted on 11/05/2013 A group of leading scientists from across Europe have launched a three-year project aimed at developing...

Synflorix™ receives positive opinion from the CHMP in Europe for additional pneumonia indication

GlaxoSmithKline plc (GSK) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an additional...

PATH Malaria Vaccine Initiative Names New Director

PATH Malaria Vaccine Initiative Names New Director Ashley Birkett, PhD, to lead key product development program at PATH WASHINGTON, Oct. 22, 2013 /PRNewswire-USNewswire/ -- PATH announced today...

Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial

BLUE BELL, Pa., Oct. 21, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C...

Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374

Astellas Pharma Inc. (TSE: 4503; Headquaters: Tokyo; President & CEO: Yoshihiko Hatanaka) and UMN Pharma Inc. (TSE: 4585; Headquaters: Akita; CEO: Tatsuyoshi Hirano) today announced that the...

Sanofi Pasteur MSD First Vaccine Company to Participate in Pilot for Rapid European Health Technology Assessment

LYON, France, October 15, 2013 /PRNewswire/ -- Sanofi Pasteur MSD is the first vaccine company to have successfully participated in a pilot testing a new rapid relative effectiveness assessment of...

CEL-SCI AND ERGOMED SIGN CO-DEVELOPMENT AND PROFIT SHARING AGREEMENT FOR MULTIKINE IN HIV/HPV CO-INFECTED WOMEN WITH CERVICAL DYSPLASIA

CEL-SCI AND ERGOMED SIGN CO-DEVELOPMENT AND PROFIT SHARING AGREEMENT FOR MULTIKINE IN HIV/HPV CO-INFECTED WOMEN WITH CERVICAL DYSPLASIA Ergomed to assume up to $3 million in clinical and regulatory...

India to scale-up pentavalent nationally

India to scale-up pentavalent nationally The GAVI Alliance welcomes the decision. The national scale-up of pentavalent vaccine in India could save a million lives. New Delhi, 10 October 2013 - The...

Newly accessible Japanese encephalitis vaccine will make saving children easier in developing countries

9 OCTOBER 2013 | GENEVA - A newly accessible vaccine against Japanese encephalitis is going to make the protection of more children in developing countries easier. The vaccine, manufactured in China,...

Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children

Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children - Malaria is a significant public health burden, claiming...

Norovirus vaccine reduces symptoms of illness by more than half, early research shows

Norovirus vaccine reduces symptoms of illness by more than half, early research shows SAN FRANCISCO – An investigational vaccine appears generally well tolerated and effective against the most...

Takeda Highlights Data from Clinical Trial of Investigational Norovirus Vaccine Candidate

Takeda Highlights Data from Clinical Trial of Investigational Norovirus Vaccine Candidate Results of Phase 1/2 Study Show Reduction in Disease Severity Following Challenge with Live Norovirus,...

Effort holds potential to control disease plaguing nearly 700 million people

Effort holds potential to control disease plaguing nearly 700 million people AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical...

Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. to Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine

Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. to Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen...

Merck Announces Global Initiative to Sharpen Commercial and R&D Focus

Merck Announces Global Initiative to Sharpen Commercial and R&D Focus WHITEHOUSE STATION, N.J., Oct 01, 2013 --Initiative targets net reduction in annual operating expenses of approximately $2.5...

NIH Renews Funding for UM Vaccine Research in Response to Emerging Public Health Issues

NIH Renews Funding for UM Vaccine Research in Response to Emerging Public Health Issues Posting Date: 09/27/2013 The University of Maryland School of Medicine's Center for Vaccine Development...

NIH expands nationwide network of Vaccine and Treatment Evaluation Units

NIH expands nationwide network of Vaccine and Treatment Evaluation Units A nationwide group of institutions that conducts clinical trials of promising candidate vaccines and therapies for infectious...

New Investment Fund Will Advance Late-Stage Vaccines and other Global Health Technologies

September 23, 2013 (NEW YORK): A new investment fund structured by JPMorgan Chase & Co. (NYSE: JPM) and the Bill & Melinda Gates Foundation will, for the first time, allow individual and...

Fluenz Tetra, four-strain nasal spray vaccine, receives positive opinion in EU from CHMP for the prevention of seasonal influenza in children

Friday, 20 September 2013 AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on Fluenz...

Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed Patients

Agenus Inc. (Nasdaq: AGEN) today announced that a recent analysis from a Phase 2 trial in patients with newly diagnosed glioblastoma multiforme (GBM) treated with Prophage Series G-100 (HSPPC-96) in...